Michael W. Henry, Md
surgery
Hospital for Special Surgery
Japan
Biography
Michael W. Henry, MD is an Assistant Attending Physician in Infectious Diseases and Internal Medicine at HSS and an Assistant Professor of Clinical Medicine at Cornell Medical School. Dr. Henry received his B.A at Haverford College and his MD at the NYU School of Medicine. He then completed his internship in Internal Medicine at New York Hospital and his residency training at the NYU Medical Center. Following his training, Dr. Henry was a Hospitalist and Teaching Attending at the Maimonides Medical Center. In 2001, he returned to NYU for fellowship training in Infectious Diseases at NYU. From 2004 to 2012 Dr. Henry was an Infectious Diseases specialist at the Bronx-Lebanon Hospital Center. He is the author of several peer-reviewed publications. Dr. Henry provides consultative and perioperative services to patients at HSS. He is working to develop clinical research programs to study infections in patients receiving new biologic agents for rheumatologic disease, and to study outcomes of patients with surgical bone/joint infections.
Research Interest
Michael W. Henry, MD is an Assistant Attending Physician in Infectious Diseases and Internal Medicine at HSS and an Assistant Professor of Clinical Medicine at Cornell Medical School. Dr. Henry received his B.A at Haverford College and his MD at the NYU School of Medicine. He then completed his internship in Internal Medicine at New York Hospital and his residency training at the NYU Medical Center. Following his training, Dr. Henry was a Hospitalist and Teaching Attending at the Maimonides Medical Center. In 2001, he returned to NYU for fellowship training in Infectious Diseases at NYU. From 2004 to 2012 Dr. Henry was an Infectious Diseases specialist at the Bronx-Lebanon Hospital Center. He is the author of several peer-reviewed publications. Dr. Henry provides consultative and perioperative services to patients at HSS. He is working to develop clinical research programs to study infections in patients receiving new biologic agents for rheumatologic disease, and to study outcomes of patients with surgical bone/joint infections.
